One of the mechanisms in which mutant KRAS contributes to tumor progression is through activation of the phosphoinositide 3-kinase (PI3K) /protein kinase B (AKT)/mTOR pathway by binding to the p110α subunit of PI3K, causing a procarcinogenic signaling cascade (Hua et al., 2019). This evidence concerns the gene KRAS and neoplasm.